250
Participants
Start Date
October 5, 2022
Primary Completion Date
March 1, 2028
Study Completion Date
June 1, 2028
Pragmatic
"Patients randomized to a strategy of switching TIM will be switched to one of the preferred agents recommended by clinical guidelines and covered by the patients' insurance formulary as part of routine care, and at the discretion of the site investigator and treating provider. No study-related medications will be provided.~Patients (and their providers) in either treatment arm will be allowed to stop or start new TIMs and other IBD-directed therapies in case of symptomatic relapse or intolerance to therapies, at the discretion of the treating provider-patient team."
RECRUITING
NYU Langone Health, New York
RECRUITING
Cornell University, New York
RECRUITING
Saratoga Schenectady Gastroenterology Associates, Burnt Hills
RECRUITING
University of Rochester, Rochester
RECRUITING
MedStar Georgetown University Hospital, Washington D.C.
WITHDRAWN
University of Virginia, Charlottesville
RECRUITING
Mayo Clinic Jacksonville, Jacksonville
WITHDRAWN
GastroOne, Germantown
RECRUITING
University of Chicago Medicine, Chicago
NOT_YET_RECRUITING
Hightower Clinical, Oklahoma City
RECRUITING
University of Texas Southwestern, Dallas
RECRUITING
Baylor College of Medicine, Houston
RECRUITING
University of Colorado, Aurora
RECRUITING
University of Utah Health, Salt Lake City
RECRUITING
Cedars-Sinai, Los Angeles
RECRUITING
UC San Diego Health, La Jolla
RECRUITING
Hoag Hospital, Irvine
RECRUITING
Sutter Health, Palo Alto
WITHDRAWN
Oregon Clinic, Portland
RECRUITING
Yale University, New Haven
RECRUITING
Dartmouth Hitchcock, Lebanon
RECRUITING
Gastroenterology Associates, Providence
Baylor College of Medicine
OTHER
Crohn's and Colitis Foundation
OTHER
Western University
OTHER
Patient-Centered Outcomes Research Institute
OTHER
University of California, San Diego
OTHER